JPH04282311A - Aerosol-type foamable wound-disinfectant - Google Patents
Aerosol-type foamable wound-disinfectantInfo
- Publication number
- JPH04282311A JPH04282311A JP3069205A JP6920591A JPH04282311A JP H04282311 A JPH04282311 A JP H04282311A JP 3069205 A JP3069205 A JP 3069205A JP 6920591 A JP6920591 A JP 6920591A JP H04282311 A JPH04282311 A JP H04282311A
- Authority
- JP
- Japan
- Prior art keywords
- wound
- disinfectant
- aerosol
- foam
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000645 desinfectant Substances 0.000 title claims abstract description 33
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 15
- 108010035532 Collagen Proteins 0.000 claims abstract description 15
- 229920001436 collagen Polymers 0.000 claims abstract description 15
- 239000000443 aerosol Substances 0.000 claims abstract description 11
- 239000003380 propellant Substances 0.000 claims abstract description 9
- 239000004088 foaming agent Substances 0.000 claims abstract description 8
- 239000012736 aqueous medium Substances 0.000 claims abstract description 6
- 238000005187 foaming Methods 0.000 claims description 8
- 239000006260 foam Substances 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 5
- 239000002736 nonionic surfactant Substances 0.000 abstract description 4
- 230000002439 hemostatic effect Effects 0.000 abstract description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract description 2
- 239000003945 anionic surfactant Substances 0.000 abstract description 2
- 230000000249 desinfective effect Effects 0.000 abstract description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract description 2
- 230000036560 skin regeneration Effects 0.000 abstract description 2
- 238000010186 staining Methods 0.000 abstract description 2
- 239000010409 thin film Substances 0.000 abstract description 2
- 229920003169 water-soluble polymer Polymers 0.000 abstract description 2
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 32
- -1 acrinoflavin Chemical compound 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 5
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003915 liquefied petroleum gas Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
【０００１】0001
【産業上の利用分野】本発明は、傷口を泡状に覆うエア
ゾール型の発泡性傷口消毒剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an aerosol-type foaming wound disinfectant that covers wounds in the form of foam.
【０００２】0002
【従来の技術】家庭を中心として、簡易な傷口消毒剤が
使用されている。これは、消毒薬を水性液としたもので
、傷口に塗布あるいはポンプ容器で霧状に噴霧すること
により使用されている。2. Description of the Related Art Simple wound disinfectants are used mainly at home. This is an aqueous disinfectant that is applied to the wound or sprayed into a mist using a pump.
【０００３】しかしこの傷口消毒剤は、液体であるので
、塗布したあとに垂れ落ちて効果が持続しなかったり、
衣服等を汚す場合がある。また、流れ落ちてしまう事お
よび透明である事から、傷口にしっかりと塗布され効果
が発揮されているかを使用者が確認できずに不安となる
ケースが多く、必要以上に多く塗布したり、不安感を拭
いきれない場合がある。また、真皮が露出したり、血が
滲み出ている状態が目で見える場合は、誰でも不安感に
かられるものであり、気持ちのよいものではない。[0003] However, since this wound disinfectant is a liquid, it may drip down after application and the effect may not last long.
May stain clothes, etc. In addition, because it runs off and is transparent, there are many cases where users become anxious because they cannot confirm whether it has been applied properly to the wound and is effective, and they may end up applying more than necessary or feeling anxious. It may not be possible to wipe it completely. Furthermore, when the dermis is exposed or blood is visibly seeping out, anyone feels anxious and it is not a pleasant experience.
【０００４】0004
【発明が解決しようとする課題】本発明は、消毒剤が傷
口に間違いなく適用された事が一目で判り、しかも、効
果および安心感が大きい傷口消毒剤を提供するものであ
る。SUMMARY OF THE INVENTION It is an object of the present invention to provide a wound disinfectant that can be seen at a glance that the disinfectant has been applied to the wound without fail, and that is highly effective and provides a sense of security.
【０００５】[0005]
【課題を解決するための手段】本発明のエアゾール型発
泡性傷口消毒剤は、傷口消毒薬、水性媒体、発泡剤およ
び噴射剤を含有する泡形成性薬剤を、エアゾール容器に
充填したことを特徴とする。[Means for Solving the Problems] The aerosol-type foaming wound disinfectant of the present invention is characterized in that an aerosol container is filled with a foam-forming agent containing a wound disinfectant, an aqueous medium, a foaming agent, and a propellant. shall be.
【０００６】[0006]
【作用】エアゾール容器から傷口消毒剤が患部（傷口）
に噴出されると、発泡して泡を形成し傷口全体を覆う。
この泡はしばらくの間持続し、やがて、あるいはガーゼ
等で押さえることにより消泡する。[Action] The wound disinfectant is applied to the affected area (wound) from the aerosol container.
When squirted, it foams to form bubbles that cover the entire wound. This foam lasts for a while, and eventually disappears by pressing with gauze or the like.
【０００７】[0007]
【実施例】図１は、本発明のエアゾール型発泡性傷口消
毒剤の実施例を示す断面図であり、エアゾール容器１１
内に、泡形成性薬剤２１が充填されている。１３はディ
ップチューブを示す。[Example] Fig. 1 is a sectional view showing an example of the aerosol type foaming wound disinfectant of the present invention.
A foam-forming agent 21 is filled inside. 13 indicates a dip tube.
【０００８】泡形成性薬剤２１は、傷口消毒薬、水性媒
体、発泡剤および噴射剤を含む。アクチュエータ１７を
押してバルブ１５を開口すると、噴出口１９より泡形成
性薬剤２１が取り出される。このとき、噴出時の衝撃（
撹拌）、噴射剤のガス化により、発泡剤を含む水性媒体
が発泡し、泡形成性薬剤２１は細かい白い泡の塊りとな
って手足等の傷口の上を覆う。そこで、薬剤２１が確実
に傷口に適用されたことが確認できる。また、白い泡で
傷口が覆われて見えなくなるので安心感が生じる。さら
に、通常の液剤と違って液垂れがないので、無駄がなく
、衣服等を汚すことがない。Foam-forming agents 21 include wound disinfectants, aqueous media, foaming agents, and propellants. When the actuator 17 is pushed to open the valve 15, the foam-forming agent 21 is taken out from the spout 19. At this time, the shock at the time of ejection (
By stirring) and gasifying the propellant, the aqueous medium containing the foaming agent foams, and the foam-forming agent 21 turns into a mass of fine white foam and covers the wound on the limb or the like. Therefore, it can be confirmed that the medicine 21 has been reliably applied to the wound. In addition, the wound is covered with white foam and becomes invisible, giving a sense of security. Furthermore, unlike ordinary liquids, there is no dripping, so there is no waste and there is no chance of staining clothes, etc.
【０００９】消泡ないし破泡することにより、傷口消毒
薬が傷口に適用され、消毒効果が得られる。泡が自然に
消泡するまでそのまま放置してもよく、また、ガーゼ等
を上から軽く押し当てて破泡し、余剰の成分をガーゼ等
に吸収して絆創膏で上からそのまま固定してもよい。[0009] By defoaming or breaking the foam, the wound disinfectant can be applied to the wound and a disinfecting effect can be obtained. You can leave it as is until the foam naturally disappears, or you can break the foam by lightly pressing gauze, etc. from above, absorb the excess ingredients into gauze, etc., and fix it with a bandage from above. .
【００１０】泡の細かさ、泡の維持時間は、発泡剤の種
類や量で調整でき、また、必要に応じて泡形成性薬剤中
に増粘剤（増泡剤）を添加することもできる。さらに、
泡形成性薬剤中にコラーゲン類や被膜形成剤を添加する
こともできる。[0010] The fineness of the foam and the foam maintenance time can be adjusted by the type and amount of the foaming agent, and if necessary, a thickener (foaming agent) can be added to the foam-forming agent. . moreover,
Collagens and film-forming agents can also be added to the foam-forming agent.
【００１１】組成中にコラーゲン類を含む場合は、上記
処置により、止血ならびに皮膚再生効果を促すことがで
きる。また、組成中に皮膜形成剤を含む場合は、消泡後
、傷口上に薄い被膜が形成されて傷口を保護する。[0011] When collagens are included in the composition, the above treatment can promote hemostasis and skin regeneration effects. Furthermore, when a film forming agent is included in the composition, a thin film is formed on the wound after defoaming to protect the wound.
【００１２】傷口消毒剤としては、ヨード、ポンピドン
ヨード、アクリノール、アクリノフラビン、ニトロフラ
ゾン、塩化ベンザルコニウム、塩化ベンゼトニウム、ク
ロルヘキシジンなどが用いられる。[0012] As the wound disinfectant, iodine, pompidone iodine, acrinol, acrinoflavin, nitrofurazone, benzalkonium chloride, benzethonium chloride, chlorhexidine, etc. are used.
【００１３】コラーゲン類のコラーゲン塩酸塩は、血液
に接触すると水分吸収し、血小板粘着、凝集を起こす。
また、コラーゲンの−ＣＯＯＨ基をエステル化した正電
荷リッチコラーゲンは、未修飾の元のコラーゲンより強
い血小板粘着を起こし、通常の消毒剤より止血効果が期
待できる。さらに、コラーゲン繊維の添加により、酸性
下でコラーゲン繊維が水を吸って膨潤し、粘着性が増し
、原液特性の変化により創傷部への付着性と皮膚成形性
が改善される。Collagen hydrochloride, which is a type of collagen, absorbs water when it comes into contact with blood, causing platelet adhesion and aggregation. In addition, positively charged rich collagen obtained by esterifying the -COOH group of collagen causes stronger platelet adhesion than the original unmodified collagen, and is expected to have a more hemostatic effect than ordinary disinfectants. Furthermore, by adding collagen fibers, the collagen fibers absorb water and swell under acidic conditions, increasing adhesiveness and improving adhesion to wound areas and skin moldability due to changes in the properties of the stock solution.
【００１４】コラーゲン類は、原液（泡形成性薬剤から
噴射剤を除いた組成）中に０．１〜３．０重量％配合す
ることが望ましい。水性媒体としては、水あるいは水−
エタノール溶液のような人体に安全なものが用いられる
。[0014] Collagen is desirably blended in an amount of 0.1 to 3.0% by weight in the stock solution (composition obtained by removing the propellant from the foam-forming agent). The aqueous medium is water or water-
A substance that is safe for the human body, such as an ethanol solution, is used.
【００１５】発泡剤としては、界面活性剤が代表的であ
り、アニオン界面活性剤、ノニオン界面活性剤などが用
いられる。ノニオン界面活性剤を用いる場合は、傷口消
毒薬剤の他の成分の可溶化のために、新油性の高いノニ
オン界面活性剤（例えば、ＨＬＢ＝２〜３）と、親水性
の高い界面活性剤（例えば、ＨＬＢ＝１０〜１２）とを
適当な割合で併用することができる。前者の具体例とし
ては、ソルビタンの高級脂肪酸エステル（スパン２０、
花王アトラス社製など）、後者の具体例としては、ソル
ビタン部分高級脂肪酸エステルのエチレンオキシド付加
物（トゥイーン２０、花王アトラス社製など）が挙げら
れる。また、ポリオキシエチレン高級アルキルエーテル
等のエチレンオキシド付加モル数を調整することによっ
ても、ＨＬＢをコントロールできる。[0015] As the foaming agent, surfactants are typical, and anionic surfactants, nonionic surfactants, etc. are used. When using a nonionic surfactant, in order to solubilize other components of the wound disinfectant, a highly oily nonionic surfactant (for example, HLB = 2 to 3) and a highly hydrophilic surfactant ( For example, HLB=10-12) can be used in combination at an appropriate ratio. Specific examples of the former include higher fatty acid esters of sorbitan (span 20,
Specific examples of the latter include ethylene oxide adducts of sorbitan partial higher fatty acid esters (Tween 20, manufactured by Kao Atlas, etc.). Furthermore, HLB can also be controlled by adjusting the number of moles of ethylene oxide added to polyoxyethylene higher alkyl ether or the like.
【００１６】増粘剤としては、カルボキシメチルセルロ
ース、カルボキシビニルポリマーなどが用いられる。[0016] As the thickener, carboxymethylcellulose, carboxyvinyl polymer, etc. are used.
【００１７】被膜形成剤としては、ポリビニルアルコー
ル、ポリ酢酸ビニル、ポリ酢酸ビニル部分加水分解物、
ポリビニルピロリドン、あるいはビニルピロリドン−酢
酸ビニル共重合体などの水溶性高分子が主に用いられる
。また、これらは増粘剤としても働き、逆に上記増粘剤
は被膜形成剤として作用するものもある。被膜形成剤は
、原液中に３〜２０重量％配合することが好ましい。Film forming agents include polyvinyl alcohol, polyvinyl acetate, polyvinyl acetate partial hydrolyzate,
Water-soluble polymers such as polyvinylpyrrolidone or vinylpyrrolidone-vinyl acetate copolymer are mainly used. These also act as thickeners, and some of the above thickeners act as film-forming agents. The film-forming agent is preferably blended in an amount of 3 to 20% by weight in the stock solution.
【００１８】噴射剤としては、エアゾール製品に使用さ
れているものが一般に用いられ、ジメチルエーテル、液
化石油ガス、フロン、炭酸ガスなどが用いられる。噴射
剤５〜２５重量部と原液７５〜９５重量部を混合して、
エアゾール容器中に充填するのが一般的である。As the propellant, those used in aerosol products are generally used, such as dimethyl ether, liquefied petroleum gas, chlorofluorocarbons, carbon dioxide gas, and the like. Mixing 5 to 25 parts by weight of propellant and 75 to 95 parts by weight of stock solution,
It is generally filled into an aerosol container.
【００１９】下記表１処方の原液８５重量部と噴射剤（
ジメチルエーテル、ＬＰガスの混合物）１５重量部とを
エアゾール容器に充填して本発明の傷口消毒剤を作成し
た。
なお、ヨウ度丁幾はヨードの８％エタノール溶液である
。85 parts by weight of the stock solution of the formulation in Table 1 below and a propellant (
A wound disinfectant of the present invention was prepared by filling an aerosol container with 15 parts by weight of a mixture of dimethyl ether and LP gas. Note that the iodine content is an 8% ethanol solution of iodine.
【００２０】[0020]
【表１】
ヨウ度丁幾
１０ ｗｔ％ ポリビニルピロリド
ン
１５ ｗｔ％ ポリ
オキシエチレン（９モル）ラウリルエーテル
０．５ｗｔ％ ポリオキシ
エチレン（１５モル）ラウリルエーテル
１．０ｗｔ％ エタノール
１２ ｗｔ
％ コラーゲン
１．５ｗｔ％ 精製水
バランス
１００ ｗｔ％[Table 1] Iodity degree
10 wt% polyvinylpyrrolidone
15 wt% polyoxyethylene (9 mol) lauryl ether
0.5wt% polyoxyethylene (15 mol) lauryl ether
1.0wt% ethanol
12wt
% collagen
1.5wt% purified water
balance
100 wt%
【００２１】こ
の傷口消毒剤を傷口に噴出したところ、わずかに着色し
た細かい白い泡が傷口表面を覆った。When this wound disinfectant was squirted onto the wound, fine, slightly colored white bubbles covered the surface of the wound.
【００２２】[0022]
【発明の効果】本発明によれば、傷口消毒薬を発泡性組
成物としてエアゾール容器に充填することにより、消毒
剤が傷口を覆うことが目で確認でき、消毒が確実に行な
え安心感が高い。また、通常の液剤のように、液垂れで
衣服を汚すこともない。[Effects of the Invention] According to the present invention, by filling an aerosol container with a wound disinfectant as a foaming composition, it is possible to visually confirm that the disinfectant covers the wound, ensuring disinfection and providing a high sense of security. . Also, unlike regular liquids, it does not drip and stain clothes.
【００２３】また、コラーゲン類を含有するときは、そ
の止血作用および皮膚再生作用を利用することができる
。[0023] Furthermore, when collagens are contained, their hemostatic and skin regenerating effects can be utilized.
【図１】図１は、本発明のエアゾール型発泡性傷口消毒
剤の実施例を示す断面図である。FIG. 1 is a sectional view showing an embodiment of the aerosol-type foaming wound disinfectant of the present invention.
１１ エアゾール容器 １３ ディップチューブ １５ バルブ １７ アクチュエータ １９ 噴出口 ２１ 泡形成性薬剤 11 Aerosol container 13 Dip tube 15 Valve 17 Actuator 19 Spout 21 Foam-forming agents
Claims (3)
噴射剤を含有する泡形成性薬剤を、エアゾール容器に充
填したことを特徴とするエアゾール型発泡性傷口消毒剤
。1. An aerosol-type foaming wound disinfectant, characterized in that an aerosol container is filled with a foam-forming agent containing a wound disinfectant, an aqueous medium, a foaming agent, and a propellant.
に含む請求項１に記載のエアゾール型発泡性傷口消毒剤
。2. The aerosol-type foaming wound disinfectant according to claim 1, wherein the foam-forming agent further contains collagen.
含む請求項１または２に記載のエアゾール型発泡性傷口
消毒剤。3. The aerosol-type foaming wound disinfectant according to claim 1, wherein the foam-forming agent further comprises a film-forming agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3069205A JPH04282311A (en) | 1991-03-08 | 1991-03-08 | Aerosol-type foamable wound-disinfectant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3069205A JPH04282311A (en) | 1991-03-08 | 1991-03-08 | Aerosol-type foamable wound-disinfectant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH04282311A true JPH04282311A (en) | 1992-10-07 |
Family
ID=13395991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3069205A Pending JPH04282311A (en) | 1991-03-08 | 1991-03-08 | Aerosol-type foamable wound-disinfectant |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH04282311A (en) |
Cited By (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07196530A (en) * | 1993-11-24 | 1995-08-01 | Aspid Sa De Cv | Polymerized collagen-based antifibrous composition |
| JPH0899873A (en) * | 1994-09-30 | 1996-04-16 | Kobayashi Pharmaceut Co Ltd | Aerosol type foamable cleaning disinfectant for wound |
| WO1996017595A1 (en) * | 1994-12-06 | 1996-06-13 | Giltech Limited | Foamable formulation and foam |
| JP2005015365A (en) * | 2003-06-25 | 2005-01-20 | Koike Kagaku Kk | Aerosol type cleansing disinfectant |
| JP2006505583A (en) * | 2002-10-25 | 2006-02-16 | フォーミックス エルティーディー． | Cosmetic and pharmaceutical foam |
| JP2007503428A (en) * | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー． | Osmotic pharmaceutical foaming agent |
| WO2007094245A1 (en) * | 2006-02-16 | 2007-08-23 | Ricoh Company, Ltd. | Fixer, fixing device, and image forming apparatus |
| JP2009104205A (en) * | 2009-02-16 | 2009-05-14 | Ricoh Co Ltd | Fixing method and image forming method |
| JP2010020352A (en) * | 2009-10-28 | 2010-01-28 | Ricoh Co Ltd | Fixing method, image forming method, fixing device and image forming apparatus |
| US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
| US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
-
1991
- 1991-03-08 JP JP3069205A patent/JPH04282311A/en active Pending
Cited By (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07196530A (en) * | 1993-11-24 | 1995-08-01 | Aspid Sa De Cv | Polymerized collagen-based antifibrous composition |
| JPH0899873A (en) * | 1994-09-30 | 1996-04-16 | Kobayashi Pharmaceut Co Ltd | Aerosol type foamable cleaning disinfectant for wound |
| US6187290B1 (en) | 1994-12-06 | 2001-02-13 | Giltech Limited | Physiologically acceptable foamable formulation and foam |
| JPH10509724A (en) * | 1994-12-06 | 1998-09-22 | ギルテク リミテッド | Foaming formulation and foam |
| WO1996017595A1 (en) * | 1994-12-06 | 1996-06-13 | Giltech Limited | Foamable formulation and foam |
| JP2006505583A (en) * | 2002-10-25 | 2006-02-16 | フォーミックス エルティーディー． | Cosmetic and pharmaceutical foam |
| US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| JP2005015365A (en) * | 2003-06-25 | 2005-01-20 | Koike Kagaku Kk | Aerosol type cleansing disinfectant |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| JP2007503428A (en) * | 2003-08-25 | 2007-02-22 | フォーミックス エルティーディー． | Osmotic pharmaceutical foaming agent |
| WO2007094245A1 (en) * | 2006-02-16 | 2007-08-23 | Ricoh Company, Ltd. | Fixer, fixing device, and image forming apparatus |
| US8019267B2 (en) | 2006-02-16 | 2011-09-13 | Ricoh Company, Ltd | Fixer, fixing device, and image forming apparatus |
| JP2007219105A (en) * | 2006-02-16 | 2007-08-30 | Ricoh Co Ltd | Fixing device, fixing method, image forming apparatus, image forming method, and fixing solution |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
| US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
| US8900553B2 (en) | 2007-12-07 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| JP2009104205A (en) * | 2009-02-16 | 2009-05-14 | Ricoh Co Ltd | Fixing method and image forming method |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
| US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
| US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US10946101B2 (en) | 2009-10-02 | 2021-03-16 | Vyne Therapeutics Inc. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| JP2010020352A (en) * | 2009-10-28 | 2010-01-28 | Ricoh Co Ltd | Fixing method, image forming method, fixing device and image forming apparatus |
| US11135315B2 (en) | 2010-11-30 | 2021-10-05 | Convatec Technologies Inc. | Composition for detecting biofilms on viable tissues |
| US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH04282311A (en) | Aerosol-type foamable wound-disinfectant | |
| US5650146A (en) | Silicone based skin care products | |
| US3987000A (en) | Sprayable polymer composition | |
| CA1229550A (en) | Aerosol gel | |
| US20130052144A1 (en) | Deodorant foams | |
| JP2003286130A (en) | Foamable aerosol composition | |
| JP5026919B2 (en) | Aerosol-type antiperspirant deodorant composition containing no water and ethanol | |
| TW200946141A (en) | Foam-shaped skin liniment | |
| WO2011051924A4 (en) | Method of wound treatment using liquid gallium nitrate | |
| JP5738575B2 (en) | Cleaning agent in container | |
| JP4616553B2 (en) | Spray composition and spray product | |
| JP2003082338A (en) | Deodorant, bacteria elimination and fragrant aerosol | |
| JPH09227347A (en) | One package hair decolorant | |
| WO1996025194A1 (en) | Medication and apparatus and method of applying medication | |
| CA3020151A1 (en) | Solid stick deodorant comprising dipropylene glycol and propylene glycol | |
| AU681436B2 (en) | Spray formulation having a cooling effect | |
| JP2001348324A (en) | Aqueous skin cleansing agent | |
| JP6163340B2 (en) | Aerosol composition and method of use | |
| JP2001247431A (en) | Aerosol composition and aerosol product for depilation | |
| US3370014A (en) | Skin cleansing compositions | |
| JP3725567B2 (en) | Atomized aerosol composition | |
| JP2795354B2 (en) | Aerosol products for human body | |
| JP7261094B2 (en) | Aerosol composition for forming peelable coating | |
| US20230052487A1 (en) | Foaming body deodorizer | |
| CA1102695A (en) | Styptic composition |